Tue, May 13, 9:07 PM (38 days ago)
**Azitra, Inc. (AZTR) Q1 2025 Financial Summary** **Financial Health and Performance:** - **Revenue:** No revenue reported as Azitra is in the pre-commercialization phase. - **Net Loss:** $3.1 million, slightly higher than the $2.9 million loss in Q1 2024. - **Operating Expenses:** $3.1 million, a 5% increase from Q1 2024, driven by higher general and administrative costs. - **Cash Flow:** Negative cash flow from operations at $3.1 million, with financing activities providing $1.7 million in cash. - **Cash Position:** $3.2 million in cash and cash equivalents as of March 31, 2025. **Profit Margins:** - **Operating Margin:** Negative, reflecting the company's focus on R&D and pre-commercial activities. - **Net Margin:** Negative, consistent with the company's stage of development. **Earnings Changes:** - **Earnings per Share (EPS):** Basic and diluted EPS of -$0.23, compared to -$4.32 in Q1 2024, reflecting the impact of stock splits. **Trends and Uncertainties:** - **R&D Focus:** Continued investment in R&D, with a decrease in R&D expenses by 15% due to reduced CMC and consultant costs. - **Funding:** Dependence on equity and debt financing to support operations and clinical trials. - **Regulatory:** Progress in clinical trials for ATR-12 and ATR-04, with expected safety results in mid-2025. - **Market Risks:** Potential impacts from trade policies and tariffs on operating expenses. **Future Operations Impact:** - **Clinical Trials:** Ongoing and planned clinical trials for ATR-12 and ATR-04. - **Partnerships:** Strategic partnerships and collaborations to advance product candidates. - **Financial Strategy:** Plans to raise additional funds through equity, debt, or strategic alliances. **Going Concern:** Management acknowledges substantial doubt about the company's ability to continue as a going concern due to significant losses and the need for additional funding. **Stock Performance:** The stock has undergone multiple splits, with a forward stock split in May 2023 and a reverse stock split in July 2024. The board is evaluating a further reverse split. **Ticker:** AZTR **Conclusion:** Azitra, Inc. is focused on advancing its pipeline of dermatology therapies, with significant investments in R&D and clinical trials. The company faces financial challenges and uncertainties but is pursuing strategic initiatives to secure additional funding and advance its product candidates.